Gynaecologic Oncology Society of Kenya (GOSK) clinical management protocol for cervical cancer in Kenya - 2026
DOI:
https://doi.org/10.59692/136ek938Keywords:
Cervical cancer, Clinical Protocol, Gynecologic Oncology, KenyaAbstract
Objective: To develop a standardized, evidence-based clinical management protocol for cervical cancer in Kenya through adaptation and contextualization of relevant international clinical practice guidelines.
Methods: The protocol was developed using a guideline adaptation approach to align recommendations from international clinical practice guidelines with the Kenyan healthcare and resource context. A multidisciplinary development group comprising gynecologic oncologists, pathologists, radiologists, oncology nurses, pharmacists, radiation oncologists, public health specialists, and patient representatives participated in the process. Relevant guidelines were identified through searches of PubMed and Google Scholar and independently appraised using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument. Selected guidelines were reviewed and their recommendations adapted and contextualized to the Kenyan setting.
Results: Four clinical practice guidelines were identified and independently appraised using AGREE II. Three guidelines were selected as source guidelines for adaptation: the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Cervical Cancer; the American Society of Clinical Oncology (ASCO) Resource-Stratified Guideline for the Management and Care of Women With Invasive Cervical Cancer; and the Korean Society of Gynecologic Oncology (KSGO) Guidelines for the Management of Cervical Cancer. The resulting protocol addresses the diagnosis, staging, treatment, surveillance, and management of recurrent cervical cancer within the Kenyan healthcare context.
Recommendations: The protocol provides evidence-based recommendations for the diagnosis, stage-specific treatment, surveillance, and management of recurrent cervical cancer, including supportive and palliative care, contextualized to the Kenyan healthcare setting.
References
1. Effah K. Transformation zone types : a call for review of the IFCPC terminology to embrace practice in low-resource settings. e cancer. 2023;1–7.
2. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Heal [Internet]. 2023;11(2):e197–206. Available from: http://dx.doi.org/10.1016/S2214-109X(22)00501-0
3. Alvarado LG, León DC De, Morales RR, Concha GS, Muñoz SB, Hernandez RS, et al. Tumor histology is an independent prognostic factor in locally advanced cervical carcinoma : A retrospective study. BMC Cancer [Internet]. 2022;1–8. Available from: https://doi.org/10.1186/s12885-022-09506-3
4. Smith HO, Tiffany MF, Qualls CR, Ph D, Key CR. The Rising Incidence of Adenocarcinoma Relative to Squamous Cell Carcinoma of the Uterine Cervix in the United States — A 24-Year Population-Based Study. 2000;105:97–105.
5. Mwaliko E, Itsura P, Keter A, De Bacquer D, Buziba N, Bastiaens H, et al. Survival of cervical cancer patients at Moi teaching and Referral Hospital, Eldoret in western Kenya. BMC Cancer [Internet]. 2023;23(1):1–11. Available from: https://doi.org/10.1186/s12885-023-11506-w
6. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10–45.
7. Patti O, Hirendra B, Julie P. Human Papilloma Virus-Associated Cervical Cancer and Health Disparities. MPDI. 2019;14–6.
8. Johnson CA, James D, Marzan A, Armaos M. Cervical Cancer: An Overview of Pathophysiology and Management. Semin Oncol Nurs [Internet]. 2019;35(2):166–74. Available from: https://doi.org/10.1016/j.soncn.2019.02.003
9. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2017;28(Supplement 4):iv72–83. Available from: https://doi.org/10.1093/annonc/mdx220
10. Petignat P, Roy M. Diagnosis and management of cervical cancer. Br Med J. 2007;335(7623):765–8.
11. Shaffi AF, Odongo EB, Itsura PM, Tonui PK, Mburu AW, Hassan AR, et al. Gynecologic Oncology Reports Cervical cancer management in a low resource setting : A 10-year review in a tertiary care hospital in Kenya. Gynecol Oncol Reports [Internet]. 2024;51(July 2023):101331. Available from: https://doi.org/10.1016/j.gore.2024.101331
12. Osok D, Karanja S, Kombe Y, Njuguna E. Cancer Patients in Kenya : A Retrospective Follow-up Study. East African Heal Res J. 2018;2(2):118–27.
13. Zhu B, Gu H, Mao Z, Narasimha M, Zhao R, Li S, et al. Global burden of gynaecological cancers in 2022 and projections to 2050. J Glob Health. 2024;14.
14. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
15. Korir A, Okerosi N, Ronoh V, Mutuma G, Parkin M. Incidence of cancer in Nairobi, Kenya (2004-2008). Int J Cancer. 2015;137(9):2053–9.
16. Mungo C, Cohen CR, Maloba M, Bukusi EA, Huchko MJ. Prevalence, characteristics, and outcomes of HIV-positive women diagnosed with invasive cancer of the cervix in Kenya. Int J Gynecol Obstet [Internet]. 2013;123(3):231–5. Available from: http://dx.doi.org/10.1016/j.ijgo.2013.07.010
17. Maranga IO, Hampson L, Oliver AW, Gamal A, Gichangi P, Opiyo A, et al. Analysis of factors contributing to the low survival of cervical cancer patients undergoing radiotherapy in Kenya. PLoS One. 2013;8(10).
18. Shvero A, Haifler M, Mahmud H, Dotan Z, Winkler H, Kleinmann N. Quality of life with tandem ureteral stents compared to percutaneous nephrostomy for malignant ureteral obstruction. Support Care Cancer [Internet]. 2022;9541–8. Available from: https://doi.org/10.1007/s00520-022-07354-2
19. Mwenda V, Mburu W, Bor J paula, Nyangasi M, Arbyn M, Weyers S, et al. Cervical cancer programme , Kenya , 2011 – 2020 : lessons to guide elimination as a public health problem. 2022;2011–20.
20. Mwenda V, Murage D, Kilonzo C, Bor J paula, Njiri P, Osiro L, et al. Baseline assessment of cervical cancer screening and treatment capacity in 25 counties in kenya, 2022. Front Oncol. 2024;(July):1–9.
21. Ngutu M, Nyamongo I. Exploring the barriers to health care and psychosocial challenges in cervical cancer management in Kenya. Int J Womens Health. 2015;791–8.
22. Comprehensive ON, Barber E, Lurie RH, Cancer C, Bradley K, Brooks R, et al. NCCN Clinical Practice Guide in oncology Cervical cancer. Natl Compr Cancer Netw. 2025;3.
23. Feldman S, Horton S, Small W, Berek JS. Management and Care of Women With Invasive Cervical Cancer : American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. Am Soc Clin Oncol. 2016;2(5).
24. Lim MC, Lee M, Shim SH, Nam EJ, Lee JY, Kim HJ, et al. Practice guidelines for management of cervical cancer in Korea : a Korean Society of Gynecologic Oncology Consensus Statement. Korean Soc Gynecol Oncol. 2017;28(3):1–17.
25. Wang M, Huang K, Wong MCS, Huang J, Jin Y, Zheng ZJ. Global Cervical Cancer Incidence by Histological Subtype and Implications for Screening Methods. J Epidemiol Glob Health [Internet]. 2024;14(1):94–101. Available from: https://doi.org/10.1007/s44197-023-00172-7
26. Santoro A, Inzani F, Angelico G, Arciuolo D, Bragantini E, Travaglino A, et al. Recent Advances in Cervical Cancer Management: A Review on Novel Prognostic Factors in Primary and Recurrent Tumors. Cancers (Basel). 2023;15(4).
27. Lee SI, Atri M. 2018 FIGO staging system for uterine cervical cancer: Enter Cross-sectional Imaging. Radiology.rsna.org. 2019;292(1):15–24.
28. Matsuo K, Machida H, Mandelbaum RS, Konishi I, Mikami M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol [Internet]. 2019;152(1):87–93. Available from: https://doi.org/10.1016/j.ygyno.2018.10.026
29. Browers M, Kho M, Browman G. Appraisal of guidelines for research & evaluation II. Can Med Assoc. 2017;
30. Tahseen R, Ahmed Y, Tariq M, Abrar S, Ali N. Compliance and clinical efficacy of vaginal dilator after radiotherapy for cervical and endometrial malignancies. ecancer. 2023;1–9.
31. Tais M, Schlottgen J, Cianci S. Clinical and Psychological Outcomes of the Use of Vaginal Dilators After Gynaecological Brachytherapy : a Randomized Clinical Trial. The authors. 2019;1936–49.
32. White ID. The Assessment and Management of Sexual Difficulties after Treatment of Cervical and Endometrial Malignancies. Clin Oncol. 2008;488–96.
33. McCormack M, Eminowicz G, Gallardo D, Diez P, Farrelly L, Kent C, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. Lancet. 2024;404(10462):1525–35.
34. Soni S, Pruthi DS. Exploring a conundrum: Evaluating the role of neoadjuvant chemotherapy preceding chemo-radiotherapy in locally advanced cervical cancer: A review article. Taiwan J Obstet Gynecol [Internet]. 2025;64(2):219–29. Available from: https://doi.org/10.1016/j.tjog.2024.10.013
35. Conte C, Della Corte L, Pelligra S, Bifulco G, Abate B, Riemma G, et al. Assessment of Salvage Surgery in Persistent Cervical Cancer after Definitive Radiochemotherapy: A Systematic Review. Med. 2023;59(2).
36. Ota T, Takeshima N, Tabata T, Hasumi K, Takizawa K. Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy. Br J Cancer. 2008;99(8):1216–20.
37. van Kol KGG, Ebisch RMF, Piek JMJ, Zusterzeel PLM, Vergeldt TFM, Bekkers RLM. Salvage surgery for patients with residual disease after chemoradiation therapy for locally advanced cervical cancer: A systematic review on indication, complications, and survival. Acta Obstet Gynecol Scand. 2021;100(7):1176–85.
38. Ku JAH, Lee SW, Jeon HG, Kim HHOE. Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences? J Urol. 2004;895–9.
39. Allen DJ, Longhorn SE, Philp T, Smith RD, Choong S. Percutaneous Urinary Drainage and Ureteric Stenting in Malignant Disease Statement of Search Strategies Used and Sources of Information Technique of Percutaneous Nephrostomy Technique of Retrograde JJ Stent Insertion. Clin Oncol [Internet]. 2010;22(9):733–9. Available from: http://dx.doi.org/10.1016/j.clon.2010.07.004
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Dr. Anwar Z. Mohamed, Dr. Yvonne N. Wekesa, Dr. Mathias O. Aketch, Dr. Victor T. Otieno, Prof. Jacqueline J. Chesang', Dr. Elly B. Odongo, Dr. Millicent S. Masinde, Dr. Wycliffe Musalia, Dr. Alfred Mokomba, Prof. Rose J. Kosgei, Prof. Eunice J. Cheserem, Dr. Margaret K. Kilonzo, Dr. Innocent O. Maranga
This work is licensed under a Creative Commons Attribution 4.0 International License.
